Á lódáil...
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
Patients received 5-azacytidine (AZA) 75 mg/m(2) intravenously daily for 7 days and sorafenib 400 mg orally twice daily continuously; cycles were repeated at ∼1-month intervals. Forty-three acute myeloid leukemia (AML) patients with a median age of 64 years (range, 24-87 years) were enrolled; 37 wer...
Na minha lista:
Main Authors: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formáid: | Artigo |
Teanga: | Inglês |
Foilsithe: |
American Society of Hematology
2013
|
Ábhair: | |
Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3674666/ https://ncbi.nlm.nih.gov/pubmed/23613521 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-01-480228 |
Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|